about
Clinical trials in head injuryA phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaPhase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant gliomaGene Therapy Applications to Cancer TreatmentPhase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerDesign of Phase II cancer trials evaluating survival probabilitiesPhase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study.Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewRapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysisStatistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trialsPhase II clinical trial of sorafenib in metastatic medullary thyroid cancerPhase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaTrial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocolA phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancerA weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II studyCombined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II studyGemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decreaseDocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaChemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cPhase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Bayesian design of single-arm phase II clinical trials with continuous monitoring.Using historical control information for the design and analysis of clinical trials with overdispersed count data.Using continuous data on tumour measurements to improve inference in phase II cancer studies.Monitoring the rates of composite events with censored data in phase II clinical trials.Ethics, data-dependent designs, and the strategy of clinical trials: time to start learning-as-we-go?COMmunication with Families regarding ORgan and Tissue donation after death in intensive care (COMFORT): protocol for an intervention studyUsing Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes."Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesionsSetting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.Phase II study of combined 5-fluorouracil/ Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer.A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic responseTreatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life
P2860
Q24543977-2606D5E5-E516-4D20-B262-819C0C934992Q24607479-767908D7-EEDC-4327-91A1-6021BCD0462DQ24644727-61625142-B45B-46FC-8D46-17497190DA0EQ24792808-31143FB2-D0F8-4553-8CDD-41AF7624480FQ24795149-2FF9F13E-C85C-4BBA-AEC3-D1ADEB69CDC0Q24802587-B23D6FD3-C890-467A-A0B7-AE25D9316E78Q24814067-9AB088B2-F3BE-459A-BA90-CD5CE0C2F4B4Q25257445-1D5EC367-560C-408A-92E0-1B25315D7021Q26766584-2811B8EA-2D75-4480-A669-4F38EFEAACC5Q26799757-4980468A-9C22-4D95-84C4-ED87D1E69FABQ26849875-4A904BC5-5A11-469F-A391-48B1C86BD2FFQ27851560-DA004A6F-5682-4865-BA97-0E2843027E58Q27853084-A9F274FE-C96F-4691-8941-A58E2691EA91Q27853209-42D2FDF5-BBB7-4E14-A318-389E2074CE35Q28209997-077724E7-5044-4D53-BA3E-C297BDA250D4Q28350903-80027AFF-BA26-4657-BA29-C5F7ED3BEE82Q28364196-355B00E5-0003-47DB-A7AF-C7EC92C92251Q28364203-7974ECF0-CE3A-4F9B-8103-A9E887FAEE5FQ28364865-DF277606-7CB9-4EAA-882B-11FD1C49882DQ28476810-F584279C-8C3A-46CA-8126-18AE83DD7F0FQ30315797-C715EC04-2740-4475-9E96-9BCA0E89288EQ30371806-59794532-D7AD-4CEF-8019-7B208072C869Q30408922-F9B73C0A-0CB1-492D-B2CA-637D4286D0A7Q30422022-1462AEE6-2311-45A8-A184-6E68CA07F970Q30422736-894CCE23-9B38-4458-A730-1A53314B3346Q30450038-93594E17-AAC7-4FC2-9E28-240C0444FCCDQ30484175-33D6B4D3-FB18-4DF5-AD27-017DDC85CD45Q30636643-325C0469-84FE-4F77-8B35-7D197D65771AQ30649937-6D0FA326-E662-4A0E-A8F9-BD03AD7E2244Q30679019-684BBDE1-CDFC-49DF-86B5-46972A4DB7AEQ30735098-A0C83D37-D272-48B9-932B-5D1BF954B316Q30835195-8434B4E1-59E5-4BB3-BE76-443B0762759AQ30868533-E6CC1096-66CD-4F56-8152-CB792A03A367Q30990540-B48B34D9-B832-4FD7-9B13-5CB9ACF7BFC5Q31048683-F6AF1B12-F04D-4E28-8988-D744ECB1E205Q31097586-A45057A6-7495-4892-955B-447FB3C92268Q31949448-BC8AE045-7D40-4995-8064-DEB611EF5A7EQ32177609-4DE66C4A-5D34-4E56-B542-D2C8B2147638Q33243912-B04298FF-40B9-494B-A5A4-2C9CB07898E7Q33270398-F86F8C3B-5685-43E1-9C76-20CB39A36F4F
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Optimal two-stage designs for phase II clinical trials.
@en
Optimal two-stage designs for phase II clinical trials.
@nl
type
label
Optimal two-stage designs for phase II clinical trials.
@en
Optimal two-stage designs for phase II clinical trials.
@nl
prefLabel
Optimal two-stage designs for phase II clinical trials.
@en
Optimal two-stage designs for phase II clinical trials.
@nl
P1476
Optimal two-stage designs for phase II clinical trials.
@en
P2093
P356
10.1016/0197-2456(89)90015-9
P407
P577
1989-03-01T00:00:00Z